Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro

Pharmacological Research

Volumn 48, Issue 3, 2003, Pages 231-236

  Chen, Huan Huan ^a   Zhou, Hui Jun ^a   Fang, Xin ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiogenesis; Artesunate; Dihydroartemisinin; Tube formation; Tumor

Indexed keywords

ARTEMISIN DERIVATIVE; ARTESUNATE; COLLAGEN GEL; DIHYDROARTEMISININ;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; WOUND;

EID: 0038689359     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00107-5     Document Type: Article

References (26)

1. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 228:1985;1049-1055.
2. Benakis A., Paris M., Loutan L., Plessas C.T., Plessas S.T. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg. 56:1997;17-23.
3. Hien T.T., White N.J. Qinghaosu. Lancet. 341:1993;603-608.
4. Dhingra V., Rao V.M., Narasu L. Current status of artemisinin and its derivatives as anti-malarial drugs. Life Sci. 66:2000;279-300.
5. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18:2001;767-773.
6. Efferth T., Davey M., Olbrich A., Rücher G., Gebbart E., Daveu R. Activity of drugs from traditional Chinese medicine towards sensitive and MDRI- or MRPI-overexpressing multidrug-resistant human CCRF-CEM leukenna cells. Blood Cells Mol. Dis. 28:2002;160-168.
7. Yang X., Pan Q., Liang Y.-G. Cancer. 16:1997;186-187. (in Chinese).
8. Wang Q., Wu L.-M., Li A.-Y., Zhao Y., Wang N. China J. Chinese Materia Med. 26:2001;707-708. (in Chinese).
9. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
10. Folkman J., Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
11. D'Amore P.A., Thompson R.N. Mechanism of angiogenesis. Annu. Rev. Physiol. 49:1987;453-464.
12. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrata N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:1993;841-844.
13. 2+ signal and tube formation induced by vascular endothelial growth factor in bovine aortic endothelial cells. Eur. J. Pharm. 398:2000;19-29.
14. Soeda S., Kozako T., Iwata K., Shimèno H., Malingre T.M., Feraly F.S., Kampinga H.H., Kenings A.W. Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: its possible mechanism of action. Biochim. Biophy. Acta. 1497:2000;127-134.
15. Woerdenbag H.J., Moskal T.A., Pras N., Kishimoto S., Sudo K., Kanamaru T., Brem H. Cytotoxicity of artemisinin-related endoperoxides to Enrlich ascites tumor cells. J. Nat. Prod. 56:1993;849-859.
16. Ingber D., Fujita T., Folkman J.et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 348:1990;555-557.
17. O'Reilly M.S., Holmgren L., Shing Y., Chen C.C., Rosenthal R.A., Moser M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
18. Berman P.A., Adams P.A. Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic. Biol. Med. 22:1997;1283-1288.
19. Zhang F., Grosser D.K., Meshnick S.R. Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. 43:1992;1805-1809.
20. Efferth T., Olbrich A., Bauer R. mRNA expression profiles for the response of human tumor lines to the anti-malarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 64:2002;617-623.
21. Kihara C., Tsunoda T., Tanaka T., Yamana H., Furukawa Y., Ono K., Kitahara O., Zembutsu H., Yanagawa R., Hirata K., Takagi T., Nakamura Y. Prediction of sensitivity of esophageal tumor to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61:2001;6474-6479.
22. Singh N.P., Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 79:2001;49-56.
23. Lai H., Singh N.P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 91:1995;41-46.
24. Sadava D., Phillips T., Lin C., Kane S.E. Tranferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 179:2002;151-156.
25. Reizenstein P. Iron, free radical and cancer. Med. Oncol. Tumor Pharmacother. 8:1991;229-233.
26. Shterman N., Kupfer B., Moroz C. Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology. 59:1991;19-25.